In recent days, the beijing intellectual property authority has officially published the results of the beijing intellectual property authority (ipr) award of 2025, in which the atomic highs corporation, by virtue of its outstanding performance in the creation, application, protection and management of intellectual property rights, succeeded in winning the title of the “beijing city intellectual property precedents unit”, which marked the authoritative endorsement of the work of the authorities in the field of intellectual property in atomic highs and highlighted the leading role of atomic highs in technological innovation in nuclear medicine。
As the core nuclear technology application enterprise under the umbrella of the central nuclear group, the deep accumulation of technology in the field of nuclear technology at atomic heights has provided a solid foundation for intellectual property work for decades. Since its inception, the atomic high court has consistently placed intellectual property at the centre of its work. The number of patent applications has continued to grow over the years, high-value patents have featured prominently, and several key technology patents have filled gaps in related areas in the country, providing new solutions for the precision treatment of tumours, etc. The company has now established a well-established intellectual property system, achieved a virtuous cycle of “innovation-protection-transformation” and successfully transformed patent technology into a clinically needed nuclear pharmaceutical product, covering a number of areas, including accelerator nuclide preparation, radioactive marking compounds, and a comprehensive nuclear medicine solution。
The evaluation of the “priority unit for intellectual property in beijing” is a double recognition of the research and development capabilities of the high-level atomic sciences and the level of intellectual property management. This will serve as an opportunity to further strengthen the strategic design of intellectual property rights, increase investment in core technological research and development, focus on the frontier areas of radioactive drugs, and foster higher-value patent outcomes. It will also improve intellectual property conversion mechanisms, promote the deeper integration of innovative technologies with clinical needs, continuously improve core competitiveness and contribute more to the high-quality development of our nuclear and pharmaceutical industry and the building of intellectual property powers。
